NASDAQ · Biotechnology · USD
Estrella Immunopharma, Inc. (ESLA) Stock Analysis
Estrella Immunopharma, Inc. (ESLA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
ESLA Key Statistics
As of Oct 21, 2026Trading
- Open
- $0.42
- Previous Close
- $0.40
- Day's Range
- 0.39–0.59
- 52-Week Range
- 0.24–3.15
- Volume
- 6.07M
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.93
Valuation
- Market Cap
- $23.92M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.25
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$13.06M
- Shares Outstanding
- 43.50M
- 1-Year Return
- −70.59%
Dividend and dates
- Avg Volume
- 1.44M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, ESLA closed at $0.55, −70.59% over 1 year.
Estrella Immunopharma, Inc. (ESLA) has a market capitalization of $23.92M.
In fiscal 2025, ESLA reported revenue of $0.00.
ESLA Stock Return by Calendar Year
Estrella Immunopharma, Inc. (ESLA) return since Sep 2021: what $10,000 became
- 1 year
- $10,000 $2,941
- −70.59%
- 5 years
- $10,000 $557
- −94.43%
- Since Sep 2021
- $10,000 $564
- −94.36%
If you had invested $10,000 in Estrella Immunopharma, Inc. (ESLA) at the close on September 14, 2021, the earliest close on record here, it would have been worth $564 at the close on October 21, 2026: −94.36% in total, −43.09% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −64.74% |
| 2025 | +30.00% |
| 2024 | +8.11% |
| 2023 | −89.21% |
| 2022 | +3.83% |
| 2021 (partial year) | +1.64% |
As of October 21, 2026.
ESLA Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$13.06M | — |
| 2024 | $0.00 | −$7.31M | — |
| 2023 | $0.00 | −$11.11M | — |
| 2022 | $0.00 | −$1.69M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$13.06M | −$13.06M | — |
| 2024 | $0.00 | — | −$7.31M | −$7.31M | — |
| 2023 | $0.00 | — | −$11.11M | −$11.11M | — |
| 2022 | $0.00 | — | −$1.69M | −$1.69M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Reported Earlier, Estrella’s EB103 Dosed Twice Three Weeks Apart In First Dose-Expansion Patient At Recommended Phase II Dose, No Treatment-Related SAEs; Dose-Escalation Delivered 100% Month 1 Complete Response In High-Dose Cohort
BenzingaEstrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase
YahooEstrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
YahooEstrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
YahooEstrella Immunopharma Activates Third Clinical Site For Ongoing STARLIGHT-1 Phase I/II Clinical Trial Evaluating EB103, CD19-Redirected ARTEMIS T-Cell Therapy, In Patients With R/R B-Cell Non-Hodgkin’s Lymphoma
BenzingaEstrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Yahoo
All 7 articles ↓Show fewer ↑
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B